×
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
S&P 500   3,825.53 (+0.01%)
DOW   30,921.29 (-0.57%)
QQQ   286.63 (+1.60%)
AAPL   141.38 (+1.76%)
MSFT   262.41 (+1.09%)
META   167.59 (+4.72%)
GOOGL   2,261.77 (+4.00%)
AMZN   113.73 (+3.81%)
TSLA   697.75 (+2.34%)
NVDA   149.13 (+2.69%)
NIO   22.20 (+3.93%)
BABA   119.40 (+2.93%)
AMD   74.89 (+1.66%)
MU   56.87 (+6.00%)
CGC   2.71 (-3.56%)
T   21.12 (-0.89%)
GE   61.88 (-2.61%)
F   11.15 (-1.50%)
DIS   96.96 (+0.85%)
AMC   12.68 (-6.28%)
PFE   51.52 (-1.51%)
PYPL   74.32 (+4.09%)
NFLX   185.43 (+3.05%)
NYSE:RCUS

Arcus Biosciences Stock Forecast, Price & News

$28.23
+1.73 (+6.53%)
(As of 07/5/2022 03:39 PM ET)
Add
Compare
Today's Range
$25.86
$28.30
50-Day Range
$17.23
$26.50
52-Week Range
$16.74
$49.10
Volume
21,881 shs
Average Volume
838,743 shs
Market Capitalization
$2.02 billion
P/E Ratio
51.33
Dividend Yield
N/A
Price Target
$60.86

Arcus Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.0% Upside
$60.86 Price Target
Short Interest
Bearish
15.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$291,220 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.03) to ($4.75) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.86 out of 5 stars

Medical Sector

675th out of 1,428 stocks

Pharmaceutical Preparations Industry

332nd out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Arcus Biosciences logo

About Arcus Biosciences (NYSE:RCUS) Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS Stock News Headlines

Why Precision BioSciences Shares Are Surging Today
Arcus Biosciences Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
366
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/05/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$60.86
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+115.6%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$52.83 million
Pretax Margin
15.39%

Debt

Sales & Book Value

Annual Sales
$382.88 million
Cash Flow
$0.93 per share
Book Value
$11.98 per share

Miscellaneous

Free Float
62,611,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
0.74














Arcus Biosciences Frequently Asked Questions

Should I buy or sell Arcus Biosciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences
or view top-rated stocks.

What is Arcus Biosciences' stock price forecast for 2022?

6 brokers have issued 1 year target prices for Arcus Biosciences' shares. Their RCUS stock forecasts range from $42.00 to $100.00. On average, they predict Arcus Biosciences' stock price to reach $60.86 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price.
View analysts' price targets for Arcus Biosciences
or view top-rated stocks among Wall Street analysts.

How has Arcus Biosciences' stock price performed in 2022?

Arcus Biosciences' stock was trading at $40.47 on January 1st, 2022. Since then, RCUS stock has decreased by 30.4% and is now trading at $28.17.
View the best growth stocks for 2022 here
.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Arcus Biosciences
.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Monday, May, 9th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of $0.83 by $1.79. The business had revenue of $18.01 million for the quarter, compared to the consensus estimate of $163.47 million. Arcus Biosciences had a net margin of 14.67% and a trailing twelve-month return on equity of 8.25%. During the same quarter in the previous year, the business earned ($1.08) EPS.
View Arcus Biosciences' earnings history
.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:
  • Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 62, Pay $932.12k)
  • Dr. Juan Carlos Jaen Ph.D., Co-Founder, Pres & Director (Age 64, Pay $838.2k)
  • Mr. Robert C. Goeltz II, Principal Financial & Accounting Officer and CFO (Age 49, Pay $613.2k) (LinkedIn Profile)
  • Ms. Jennifer A. Jarrett M.B.A., COO & Director (Age 51, Pay $828.2k) (LinkedIn Profile)
  • Ms. Carolyn C. Tang J.D., Gen. Counsel & Corp. Sec. (Age 43, Pay $603.2k) (LinkedIn Profile)
  • Dr. Stephen Young Ph.D., Sr. VP of Technology & Quantitative Biology (Age 53)
  • Dr. Jonathan Yingling Ph.D., Chief Scientific Officer (Age 53)
  • Ms. Katherine Bock, VP of Investor Relations & Corp. Strategy
  • Holli Kolkey, VP of Corp. Communications
  • Ms. Yvonne Gehring, Sr. VP of HR & Operations

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arcus Biosciences own?

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $28.17.

How much money does Arcus Biosciences make?

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $2.02 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.55 on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 366 workers across the globe.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for Arcus Biosciences is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.

This page (NYSE:RCUS) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.